Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling

Activating mutations of the FMS‐like tyrosine kinase 3 gene (FLT3) occur in approximately one‐third of patients with acute myeloid leukaemia (AML) and predict for a poor outcome. Heat shock protein 90 (Hsp90) is a molecular chaperone that is frequently used by cancer cells to stabilise mutant oncoproteins. Mutant FLT3 is chaperoned by Hsp90 in primary AML blasts whereas unmutated FLT3 is not, making Hsp90 inhibitors potentially useful therapeutically. The present study showed that inhibition of Hsp90 by 17‐allylamino‐17‐demethoxygeldanamycin (17‐AAG) was cytotoxic to primary AML cells expressing mutant FLT3. Inhibition of Hsp90 results in altered downstream signalling effects in primary AML cells with disruption of Janus kinase–signal transducer and activator of transcription (JAK‐STAT), mitogen‐activated protein kinase and phosphatidylinositol 3/AKT signalling pathways. Co‐treatment of blasts with 17‐AAG and cytarabine resulted in a synergistic or additive effect in approximately 50% of AML cases tested. Our results confirm that Hsp90 is a valid molecular target in the therapy of AML. Inhibition of Hsp90 in parallel with conventional AML therapies may have particular benefit in those patients with the poor prognostic FLT3 mutant disease.

[1]  Adam J Mead,et al.  The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. , 2008, Blood.

[2]  P. Meltzer,et al.  Constitutive Fms‐like tyrosine kinase 3 activation results in specific changes in gene expression in myeloid leukaemic cells , 2007, British journal of haematology.

[3]  Q. Waisfisz,et al.  Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples , 2006, Leukemia.

[4]  Chunaram Choudhary,et al.  Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation. , 2005, Cancer research.

[5]  H. Dombret,et al.  Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group , 2005, Leukemia.

[6]  R. Mesa,et al.  Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine. , 2005, Blood.

[7]  S. Lakhani,et al.  Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Beliakoff,et al.  Hsp90: an emerging target for breast cancer therapy , 2004, Anti-cancer drugs.

[9]  A. Scuto,et al.  Cotreatment with 17-Allylamino-Demethoxygeldanamycin and FLT-3 Kinase Inhibitor PKC412 Is Highly Effective against Human Acute Myelogenous Leukemia Cells with Mutant FLT-3 , 2004, Cancer Research.

[10]  John H Kersey,et al.  FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  J. Radich,et al.  FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. , 2003, Blood.

[12]  L. Whitesell,et al.  The stress response: implications for the clinical development of hsp90 inhibitors. , 2003, Current cancer drug targets.

[13]  J. Radich,et al.  The role of FLT3 in haematopoietic malignancies , 2003, Nature Reviews Cancer.

[14]  K. Camphausen,et al.  Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17- demethoxygeldanamycin: a multitarget approach to radiosensitization. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  J. Downing,et al.  The AML1-ETO fusion gene promotes extensive self-renewal of human primary erythroid cells. , 2003, Blood.

[16]  A. Burnett,et al.  Protein kinase C mediates mutant N-Ras-induced developmental abnormalities in normal human erythroid cells. , 2002, Blood.

[17]  H. Saito,et al.  Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors , 2002, Leukemia.

[18]  T. Naoe,et al.  Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain , 2002, Oncogene.

[19]  L. Neckers,et al.  Hsp90 inhibitors as novel cancer chemotherapeutic agents. , 2002, Trends in molecular medicine.

[20]  M. Blagosklonny.  Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs , 2002, Leukemia.

[21]  山本 幸也,et al.  Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies , 2002 .

[22]  D. Gilliland,et al.  FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. , 2002, Blood.

[23]  J. Buchner,et al.  Hsp90: Chaperoning signal transduction , 2001, Journal of cellular physiology.

[24]  G. Kroemer,et al.  Heat shock proteins: endogenous modulators of apoptotic cell death. , 2001, Biochemical and biophysical research communications.

[25]  B. Smith,et al.  A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. , 2001, Blood.

[26]  P. Workman,et al.  Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. , 2001, Cancer research.

[27]  T. Naoe,et al.  Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. , 2001, Blood.

[28]  W. Berdel,et al.  Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. , 2000, Blood.

[29]  D. Small,et al.  Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation , 2000, Leukemia.

[30]  W. Leonard,et al.  Essential Role of Signal Transducer and Activator of Transcription (Stat)5a but Not Stat5b for Flt3-Dependent Signaling , 2000, The Journal of experimental medicine.

[31]  P. Workman,et al.  Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone , 2000, Oncogene.

[32]  L. Neckers,et al.  The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. , 2000, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[33]  Roy Garcia,et al.  STATs in oncogenesis , 2000, Oncogene.

[34]  T. Naoe,et al.  Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines , 2000, Oncogene.

[35]  W. Berdel,et al.  Flt 3 mutations from patients with acute myeloid leukemia induce transformation of 32 D cells mediated by the Ras and STAT 5 pathways , 2000 .

[36]  H. Saito,et al.  Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product , 1998, Leukemia.

[37]  L. Neckers,et al.  The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin , 1998, Cancer Chemotherapy and Pharmacology.

[38]  T. Naoe,et al.  Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines , 1997, Leukemia.

[39]  H. Kaneko,et al.  Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. , 1996, Leukemia.

[40]  L. Neckers,et al.  Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway , 1996, Molecular and cellular biology.

[41]  Mark S. Boguski,et al.  Proteins regulating Ras and its relatives , 1993, Nature.

[42]  R. Jove,et al.  Raf exists in a native heterocomplex with hsp90 and p50 that can be reconstituted in a cell-free system. , 1993, The Journal of biological chemistry.

[43]  D. Birnbaum,et al.  Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells. , 1993, Blood.

[44]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.